disease

A unique collection of 1408 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

Well-chosen 1246 compounds with unique structures targeting nervous system;

A unique collection of 857 compounds with anti-PD activities or acting on main drug targets of PD can be used for HTS and HCS.

A unique collection of 986 compounds with anti-AD activities or acting on main drug targets of AD can be used for HTS and HCS.

A unique collection of 2154 compounds related to neurodegenerative diseases can be used for HTS or HCS；

A unique collection of 1283 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

A unique collection of 1513 neurotransmitter receptor compounds, can be used for HTS and HCS screening；

A unique collection of 683 diabetes related compounds;

A unique collection of 1147 compounds targeting ion channels for research in ion channels-related diseases and ion channel drug discovery;

A unique collection of 2247 anti-obesity compounds for high throughput and high content screening;

A unique collection of 614 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 1197 stem cell differentiation signaling targeted compounds for high throughput and high content screening;

A unique collection of 4533 pure natural products and their derivatives with known biological activity for drug discovery, pharmacological study, stem cell differentiation, fingerprint study and quality research, and can be used for high throughput screen

A collection of 499 selected human endogenous metabolites for high throughput and high content screening.

A unique collection of 485 PPI-related compounds for drug screening;

A unique collection of 492 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 2540 compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 784 compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 3111 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 210 ubiquitination related small chemicals can be used for high throughput and high content screening；

A unique collection of 514 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 779 ferroptosis signaling pathway related compounds, a powerful tool for new target identification, drug discovery, and mechanism study；

A unique collection of 701 preclinical compounds for high throughput screening (HTS) and high content screening (HCS);

128 methylation-related compounds that can be used for high-throughput and high-content screening.

Large quantity: contains 163,000 natural product derivatives and the number is continuously updating;

A unique collection of 759 cytoskeleton-related compounds, can be used for HTS and HCS；

A unique collection of 2238 pancreatic cancer related compounds can be used in HTS and HCS;

A unique collection of 118 sodium channel blockers and agonists for high throughput and high content screening;

A collection of 1279 TCM monomers with anti-inflammatory activity or targeting molecular therapeutic targets in inflammation, a powerful tool for drug discovery and mechanism study；

A unique collection of 1813 reprogramming signaling pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 565 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

419 well-chosen unique anti-parasitic small molecules;

A unique collection of 531 nuclear receptor signaling targeted compounds for high throughput and high content screening;

A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；

A unique collection of 219 natural products related to gastroenteritis for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1001 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening；

A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS);

678 hypertension-related small molecules for high-throughput and high-content screening.

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening；

A unique collection of 1180 potential anti-fibrosis compounds, can be used in HTS and HCS;

76 exosome-related compounds that can be used for high-throughput and high-content screening.